Norman Simpson
Alignment Healthcare (NASDAQ: ALHC) saw a top executive sell $550,000 worth of stock on June 18, 2026 — but the details behind the Alignment Healthcare insider sale suggest it's far less alarming than the headline figure might imply.
At a Glance
- EVP Joseph Konowiecki sold 25,000 shares at $22.00 each under a prearranged Rule 10b5-1 plan
- He still holds more than 1.15 million shares worth roughly $25.2 million at June 18 close
- Q1 2026 revenue jumped 33.3% year over year to $1.24 billion
- Membership rose 30.9% to approximately 284,800 members in Q1
- Management raised full-year guidance across multiple key metrics
Who Sold and How Much Did It Matter?
Joseph S. Konowiecki, Executive Vice President of Corporate Affairs, filed a Form 4 with the SEC disclosing the open-market sale of 25,000 shares. The transaction, priced at $22.00 per share, totaled $550,000. After the sale, Konowiecki retained 1,153,816 shares — meaning he offloaded just over 2% of his direct holdings.
Critically, the sale was made under a Rule 10b5-1 trading plan adopted back in March. These prearranged plans are set up in advance, often months before any trades are executed, which largely removes the implication that an executive is acting on inside knowledge of the company's near-term prospects. Investors generally shouldn't read too much into the timing of 10b5-1 sales.
The Business Behind the Trade
Alignment Healthcare operates in the Medicare Advantage sector, running an integrated platform that includes direct ownership of Medicare Advantage plans. The company targets high-need senior populations and leans on technology to deliver what it describes as personalized care. That model has been gaining traction fast.
First-quarter 2026 results told a compelling story. Revenue reached $1.24 billion, a 33.3% increase over the same period a year earlier. Membership grew 30.9% to roughly 284,800 members. Perhaps more telling: the company swung from a net loss to net income of $11.4 million, and adjusted EBITDA soared nearly 88% to $37.9 million. CEO John Kao characterized the quarter as a demonstration of the company's ability to "grow with discipline," pointing to gains in sales, clinical operations, and cost control.
Full-Year Picture
| Metric | Value |
|---|---|
| Revenue (trailing 12 months) | $4.26 billion |
| Net income (trailing 12 months) | $19.81 million |
| 1-year stock price change | +56.59% |
| Q1 2026 revenue | $1.24 billion |
| Q1 2026 adjusted EBITDA | $37.9 million |
| Q1 2026 membership | ~284,800 |
Management raised the midpoint of full-year guidance for membership, revenue, adjusted gross profit, and adjusted EBITDA after the Q1 print — a signal of confidence that goes considerably further than a single executive trimming a small slice of his position.
What Investors Should Actually Focus On
The Medicare Advantage market is consolidating around scale and profitability. Many healthcare companies have stumbled on that combination lately, yet Alignment appears to be threading the needle — accelerating member growth while simultaneously improving margins. The stock is up more than 56% over the past year, so Konowiecki's decision to monetize a sliver of his stake is entirely ordinary under these circumstances.
The real question for long-term holders isn't whether an executive sold $550,000 worth of shares. It's whether Alignment can keep converting rapid membership growth into durable profit — and right now, the Q1 numbers and raised guidance suggest the trajectory is intact.
Frequently Asked Questions
What is a Rule 10b5-1 trading plan?
A Rule 10b5-1 plan is a prearranged agreement that lets corporate insiders schedule stock sales in advance, typically months before the transactions occur. Because the plan is set up before any material nonpublic information is known, these sales carry far less signal value than discretionary open-market sales.
How large is Konowiecki's remaining stake in Alignment Healthcare?
After the June 18 sale, Konowiecki directly held 1,153,816 shares. Based on the June 18 market close of $21.86, that position was worth approximately $25.2 million.
How has Alignment Healthcare's stock performed recently?
ALHC shares gained roughly 56.6% in the twelve months leading up to June 18, 2026, significantly outpacing broader market benchmarks during that stretch.
Is Alignment Healthcare profitable?
On a trailing twelve-month basis, the company reported net income of $19.81 million on revenue of $4.26 billion. In Q1 2026 alone, it swung to net income of $11.4 million after posting a loss in the prior-year quarter.
Where Alignment Goes From Here
With raised guidance, improving profitability, and membership growth accelerating into the mid-30% range, Alignment Healthcare enters the back half of 2026 with meaningful momentum. One executive trimming 2% of his holdings doesn't change that picture — if anything, the size of what he kept says more than what he sold.
